Send to

Choose Destination
See comment in PubMed Commons below
Surg Neurol Int. 2014 May 8;5:64. doi: 10.4103/2152-7806.132138. eCollection 2014.

Glioblastoma multiforme: State of the art and future therapeutics.

Author information

Department of Neurosurgery, Division of Oncology, New York University School of Medicine, NY, USA.
Department of Pediatrics, Division of Oncology, New York University School of Medicine, NY, USA.



Glioblastoma multiforme (GBM) is the most common and lethal primary malignancy of the central nervous system (CNS). Despite the proven benefit of surgical resection and aggressive treatment with chemo- and radiotherapy, the prognosis remains very poor. Recent advances of our understanding of the biology and pathophysiology of GBM have allowed the development of a wide array of novel therapeutic approaches, which have been developed. These novel approaches include molecularly targeted therapies, immunotherapies, and gene therapy.


We offer a brief review of the current standard of care, and a survey of novel therapeutic approaches for treatment of GBM.


Despite promising results in preclinical trials, many of these therapies have demonstrated limited therapeutic efficacy in human clinical trials. Thus, although survival of patients with GBM continues to slowly improve, treatment of GBM remains extremely challenging.


Continued research and development of targeted therapies, based on a detailed understanding of molecular pathogenesis can reasonably be expected to yield improved outcomes for patients with GBM.


Glioblastoma multiforme; gene therapy; immunotherapy; molecularly targeted therapy

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
    Loading ...
    Support Center